SCHEMBL25758634

SCHEMBL25758634

C=C1Nc2ccc(C)cc2[C@H]1C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
TP53 P04637 2/20 0.39
CHRM1 P11229 1/20 0.33
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
ATM Q13315 1/20 0.33
KDM4E B2RXH2 4/20 0.33
ALDH1A1 P00352 4/20 0.33
GAA P10253 2/20 0.33
MAOB P27338 1/20 0.32
CHRNB2 P17787 1/20 0.32
CHRNA4 P43681 1/20 0.32
HPGD P15428 2/20 0.31
HSD17B10 Q99714 2/20 0.31
GAPDH P04406 1/20 0.31
POLB P06746 1/20 0.31
HSPA1A P0DMV8 1/20 0.31
ALOX15 P16050 1/20 0.31
APEX1 P27695 1/20 0.31
PTPN7 P35236 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25758624 0.86 BRD4 (0.33) MAPTTP53CHRM1KDM4EALDH1A1
SCHEMBL15723716 0.86 BRD4 (0.33) MAPTTP53CHRM1KDM4EALDH1A1
SCHEMBL25758621 0.81 MAPT (0.39) MAPTTP53CHRM1ATMMAOB
SCHEMBL25758640 0.81 MAOB (0.41) MAPTMEN1KMT2AMAOBCHRNB2
SCHEMBL25758503 0.81 MAPT (0.39) MAPTTP53CHRM1ATMMAOB
SCHEMBL25761239 0.79 MAPT (0.55) MAPTTP53MEN1KMT2AATM
SCHEMBL15723865 0.79 MAPT (0.55) MAPTTP53MEN1KMT2AATM
SCHEMBL15723614 0.77 HTR5A (0.36) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL25758588 0.77 HTR5A (0.36) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL25758616 0.71 CHRM1 (0.35) MAPTTP53CHRM1CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20230192663-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192663-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTSV, CTRL, CTSL MAPT 2276/4885TP53 527/4885CHRM1 4882/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV MAPT 2314/4885TP53 524/4885CHRM1 4881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.